Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Recruiting · NCT06883526 · Registry updated 2026-01-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-05 | NCT06883526 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 23 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | China | 29 |